Kura Historical Cash Flow
| KURA Stock | USD 7.77 0.11 1.40% |
Analysis of Kura Oncology cash flow over time is an excellent tool to project Kura Oncology future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 73.8 M or Change In Working Capital of 9.4 M as it is a great indicator of Kura Oncology ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Kura Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kura Oncology is a good buy for the upcoming year.
Kura |
About Kura Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Kura balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Kura's non-liquid assets can be easily converted into cash.
Kura Oncology Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Kura Oncology's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Other Cashflows From Financing Activities is projected to increase significantly based on the last few years of reporting. The current year's Change In Working Capital is expected to grow to about 9.4 M, whereas Change In Cash is projected to grow to (12.4 M).
Kura Oncology cash flow statement Correlations
Click cells to compare fundamentals
Kura Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kura Oncology cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 299.6M | (234.8M) | (38.9M) | (14.5M) | (13.0M) | (12.4M) | |
| Free Cash Flow | (72.0M) | (105.7M) | (110.7M) | (125.0M) | (112.5M) | (106.9M) | |
| Total Cash From Operating Activities | (69.8M) | (104.6M) | (110.1M) | (124.8M) | (112.3M) | (106.7M) | |
| End Period Cash Flow | 325.7M | 90.9M | 52.0M | 37.3M | 42.9M | 40.3M | |
| Other Cashflows From Financing Activities | 10.2M | (611K) | 3.8M | 1.2M | 1.4M | 2.4M | |
| Total Cash From Financing Activities | 469.3M | (3.4M) | 38.6M | 94.8M | 109.0M | 73.8M | |
| Change In Working Capital | 6.4M | (3.2M) | (3.0M) | 7.8M | 9.0M | 9.4M | |
| Begin Period Cash Flow | 26.1M | 325.7M | 90.9M | 51.8M | 59.6M | 43.1M | |
| Other Non Cash Items | 410K | 399K | 1.7M | (8.9M) | (8.0M) | (7.6M) | |
| Net Income | (89.6M) | (130.5M) | (135.8M) | (152.6M) | (137.4M) | (130.5M) | |
| Sale Purchase Of Stock | 132.2M | 108.2M | 459.3M | 29.1M | 33.5M | 31.8M | |
| Cash And Cash Equivalents Changes | 10.0M | 299.6M | (234.8M) | (38.9M) | (35.0M) | (33.2M) | |
| Cash Flows Other Operating | (1.2M) | 494K | (686K) | (2.4M) | (2.1M) | (2.0M) | |
| Change To Liabilities | 1.1M | 5.9M | (2.5M) | (618K) | (556.2K) | (528.4K) | |
| Investments | (97.8M) | (125.7M) | 32.6M | (74.0M) | (66.6M) | (69.9M) | |
| Stock Based Compensation | 12.8M | 23.6M | 26.3M | 28.1M | 32.3M | 33.9M | |
| Total Cashflows From Investing Activities | (46.3M) | (99.9M) | (126.8M) | 32.6M | 29.4M | 30.8M | |
| Depreciation | 194K | 558K | 759K | 849K | 976.4K | 1.0M | |
| Change To Operating Activities | (992K) | 707K | (706K) | (2.2M) | (2.0M) | (1.9M) | |
| Change To Netincome | 9.4M | 12.8M | 24.2M | 26.4M | 30.3M | 31.9M | |
| Other Cashflows From Investing Activities | (46.3M) | (97.8K) | (125.7K) | 33.3K | 38.2K | 40.2K | |
| Issuance Of Capital Stock | 459.3M | 324.3M | 24.7M | 118.3M | 106.5M | 155.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.